Frontline Immunotherapy Improves OS Vs BRAF/MEK Inhibitors in BRAF+ NSCLC

First-line immune checkpoint inhibitors (ICIs) with or without chemotherapy conferred an improvement in overall survival (OS)—albeit with lower response rates and similar progression-free survival (PFS)—compared with BRAF and MEK inhibitors…